Loading…
← CockpitCompetitor Analysis › THYROCARE.NS Thyrocare Technologies LtdOpen in the cockpit ↗

Thyrocare Technologies LtdTHYROCARE.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Medical/Nursing Services
Momentum neutral 46
Mkt cap
$858M
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$3.66M
20-day average traded
Fwd P/E
36.0×
forward earnings
ROIC−WACC
+30.3 pp
WACC 13.9%
Hurdle
+18 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · INR₹503.60
1D-0.7%
1W+3.0%
1M+6.9%
3M-17.2%
6M+7.0%
YTD+13.0%
1Y+8.0%
ATR %3.9%
Beta0.48
52w lowhigh23.9% off high

What Thyrocare Technologies does

Employees: 2,092

Thyrocare Technologies at a glance

Size Thyrocare Technologies (THYROCARE.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $858M, the 652nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹503.60 on 18 Nov 2026.

Performance Over six months the shares gained 7.0%, against +0.9% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 22.0% over the last twelve months (peer median +5.2%); the operating margin is 25.6% (peer median 6.8%).

Valuation It trades at 36.0× forward earnings against a peer median of 17.7× (4th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 30.3 points above its cost of capital (13.9% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026THYROCARE.NS 106Peer median 104
Six months, rebased to 100: Thyrocare Technologies against the median of its 20 peers (local-currency closes).

Thyrocare Technologies financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹9.30B₹8.29B₹6.87B₹5.72B₹5.27B
Revenue growth—+21%+20%+9%—
Gross profit₹4.76B₹3.10B₹2.28B₹1.81B₹1.50B
EBITDA₹2.99B₹2.65B₹1.94B₹1.43B₹1.25B
Net income₹1.44B₹1.63B₹915M₹708M₹645M
Free cash flown/a₹1.95B₹1.48B₹1.03B₹870M
Capital expendituren/a₹209M₹335M₹616M₹436M
Total debt₹569M₹507M₹247M₹423M₹233M

Quarterly statements and history in the cockpit →

Thyrocare Technologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%TTALO4694195940REG1951AHCO688315GMRSNEPHROPLUSFLGTWELLGDRXNUTXMETROPOLISOPKPNTGDIADNALMRITHYROCARE.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Thyrocare Technologies is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×TTALO4694195940REG1951688315GMRSNEPHROPLUSWELLGDRXNUTXMETROPOLISPNTGDIACLARILMRITHYROCARE.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Thyrocare Technologies is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%TTALO4694REGGMRSNEPHROPLUSWELLNUTXTHYROCARE.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Thyrocare Technologies is the large dot.

Thyrocare Technologies competitors and peer comparison

How Thyrocare Technologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Thyrocare Technologies against its 20 peers (data as of 18 Nov 2026)
MeasureTHYROCARE.NSPeer medianRank in peer set
1-month return+6.9%+1.5%5th highest of 21
6-month return+7.0%+0.9%10th highest of 21
Distance from 52-week high-23.9%-25.5%10th highest of 21
Revenue growth (TTM)+22.0%+5.2%4th highest of 21
Operating margin25.6%6.8%2nd highest of 21
Forward P/E36.0×17.7×4th most expensive of 17
Growth the price implies (Req g, 7 yrs)28.5%8.7%3rd most demanding of 17
Growth delivered (Del g)+10.9%+12.3%8th lowest of 17
Hurdle (Req g minus delivered)+17.6 pp-4.9 pp2nd most demanding of 17
ROIC minus cost of capital+30.3 pp-2.5 pphighest of 20
EV / EBITDA26.3×8.7×2nd most expensive of 17
Net debt / EBITDA-0.5×2.6×4th least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%12.3×-4.7%+12.2%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a

Questions

Which companies are Thyrocare Technologies's closest peers?
The cockpit's peer set: Terveystalo Oy (TTALO.HE), BML (4694.T), HK inno.N (195940.KS), Regis Healthcare (REG.AX), Jinxin Fertility (1951.HK), AdaptHealth (AHCO), Novogene (688315.SS), GMR Solutions (GMRS).
Is Thyrocare Technologies expensive compared with its peers?
On forward p/e it trades at 36.0× against a peer median of 17.7×, 4th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Thyrocare Technologies stock performed?
Over six months to 18 Nov 2026 the shares returned +7.0% against +0.9% for the median peer; over one year +8.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.